论文部分内容阅读
有人假设,肝硬化患者肾脏前列腺素E_2(PGE_2)的基础生成量和利尿剂刺激生成量的减少为钠潴留的决定因素。为试图确定这一假设是否正确,作者进行下列研究。 19例慢性重度肝病临床稳定的患者(酒精性肝硬化17例,乙型肝炎1例,继发性胆汁性肝硬化1例)分成三组:A组5例无腹水,体重不变五天以上;B组7例有腹水,利尿剂治疗有效;C组7例经中至大剂量2～3种利尿剂并用无效,故作腹膜腔静脉回流术。每日钠摄入量:A组2g,B、C两组0.5或1.0g。BC两组试验前,停用安体舒通至少7天,停用其他利尿剂至少3天。B、C两组在10秒内静脉注入速尿80mg,收集给药后1小时尿标本备测。
It has been hypothesized that the basal production of prostaglandin E2 (PGE2) and the reduction of diuretic stimuli in cirrhotic patients are the determinants of sodium retention. In an attempt to determine whether this assumption is correct, the authors conducted the following study. Nineteen patients with clinically stable chronic severe hepatopathy (17 with alcoholic cirrhosis, 1 with hepatitis B, and 1 with secondary biliary cirrhosis) were divided into three groups: group A, 5 patients with ascites without change in body weight over five days ; In group B, 7 cases had ascites and diuretic treatment was effective; 7 cases in group C received 2 to 3 types of diuretics with medium to large dose and were ineffective. Therefore, they were given retroperitoneal venous reflux. Daily sodium intake: A group 2g, B, C two groups of 0.5 or 1.0g. Spironolactone was discontinued for at least 7 days before discontinuation of other diuretics for at least 3 days prior to the two BC trials. B, C both groups within 10 seconds of furosemide 80mg intravenous injection, urine samples collected one hour after the test.